COVID-19 Nirmatrelvir Ritonavir tablets: Hyderabad’s Zenara Pharma has launched two tablets in the fight against Corona. The company said that Nirmatrelvir and Ritonavir tablets have been launched in a combi pack to treat patients with mild to moderate symptoms of COVID-19. Genara Pharma is a wholly owned subsidiary of Biofor India Pharmaceuticals. Regarding the price, the company said that the price of both the tablets will be Rs 5,200 per box. There will be 20 tablets of Nirmalvir 150 ml and 10 tablets of Ritonavir 100 mg.
Got green signal from FDA
The tablet will be sold under the brand name ‘PaxGen’. These drugs are being manufactured at Zenara’s US FDA and EU-approved state-of-the-art facility in Hyderabad. It is worth noting that Genara Pharma got approval from the Central Drugs Standard Control Organization (CDSCO) last month to manufacture and sell this product.
Know what the Managing Director of Zenara said
Dr Jagdish Babu Rangisetty, Co-Founder and Managing Director, Zenara Pharma said that we have launched this product in India with an aim to bring the best treatment options against COVID within the reach of patients in our country.
first oral tablet against corona
He told that the success of the product was approved by the US Food and Drug Administration (FDA) in December 2021. It can be used in the treatment of mild to moderate COVID-19 in adults. This was the first oral tablet approved by the US FDA.
The risk is reduced by 89%
Studies have also indicated that the risk of death or hospitalization is reduced by 89% when taken in a timely manner against COVID. The tablet can be consumed by oneself at home after being prescribed by the doctor. The medicine is also said to be safe.
You read this news on the country’s number 1 Hindi website Zeenews.com/Hindi
(with agency input)